Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 11/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 11/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 8/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 8/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 1.00 |
| ▸ | MAPT | P10636 | 8/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 7/20 | 1.00 |
| ▸ | RECQL | P46063 | 7/20 | 1.00 |
| ▸ | CYP1A1 | P04798 | 7/20 | 1.00 |
| ▸ | CYP1B1 | Q16678 | 7/20 | 1.00 |
| ▸ | XDH | P47989 | 7/20 | 1.00 |
| ▸ | FTO | Q9C0B1 | 7/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 6/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 6/20 | 1.00 |
| ▸ | APP | P05067 | 6/20 | 1.00 |
| ▸ | POLH | Q9Y253 | 6/20 | 1.00 |
| ▸ | POLB | P06746 | 5/20 | 1.00 |
| ▸ | TP53 | P04637 | 5/20 | 1.00 |
| ▸ | IPMK | Q8NFU5 | 5/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quercetin SCHEMBL29723041 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4KDM4E | |
| Quercetin SCHEMBL31507620 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4KDM4E | |
| Quercetin SCHEMBL29353785 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4KDM4E | |
| Quercetin SCHEMBL19723 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4KDM4E | |
| Quercetin SCHEMBL17629824 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4KDM4E | |
| Quercetin SCHEMBL118425 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4KDM4E | |
| Quercetin SCHEMBL6756842 | 0.99 | MEN1 (0.97) | MEN1KMT2ACYP1A2CYP3A4KDM4E | |
| Quercetin SCHEMBL3786991 | 0.99 | MEN1 (0.97) | MEN1KMT2ACYP1A2CYP3A4KDM4E | |
| Quercetin SCHEMBL22103 | 0.99 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4KDM4E | |
| Quercetin SCHEMBL21585504 | 0.99 | MEN1 (0.97) | MEN1KMT2ACYP1A2CYP3A4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 970 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075560-A | Application of total flavonoids of sea buckthorn leaves in preparing medicines for treating ulcerative colitis | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026107510-A1 | HOT-MELT ADHESIVE COMPOSITION AND METHOD OF APPLICATION | BIOBOND ADHESIVES, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| CN-122036669-A | 3' -O-sodium sulfonate quercetin and preparation method and medical application thereof | 查孝柱 | 2026-05-15 | — | — | CN | claimed |
| EP-4514146-B1 | A COMBINATION FOR USE IN THE PREPARATION OF A DRINKABLE FOAMING OR FOAMABLE LIQUID, A DEVICE AND A METHOD FOR PREPARING AND DISPENSING A DRINKABLE FOAMING OR FOAMABLE LIQUID | BAR ON B V (BE) | 2026-05-13 | — | — | EP | claimed |
| CN-122029176-A | Containing a plurality of oligonucleotides modified oligonucleotides | 阿达尔克斯制药有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-122028913-A | Oligonucleotides containing ligands in nucleobases, 2 'or 3' positions | 阿达尔克斯制药有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-122029177-A | Oligonucleotides containing multiple ligands and/or lipids | 阿达尔克斯制药有限公司 | 2026-05-12 | — | — | CN | claimed |
| EP-4727563-A1 | AGENTS FOR USE IN A METHOD OF TREATING AN ACUTE LIVER DISEASE SUBJECT | Beatson Institute for Cancer Research (GB) | 2026-04-22 | — | — | EP | claimed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | claimed |
| US-20260090992-A1 | COMPOSITIONS AND APPLICATIONS THEREOF | KENVUE BRANDS LLC (US) | 2026-04-02 | — | — | US | claimed |
| CN-114577974-A | Quality detection method for artemisia anomala standard decoction | 湖南新汇制药股份有限公司 | 2022-06-03 | — | — | CN | claimed |
| WO-2022115035-A1 | PROBIOTIC COMPOSITIONS AND METHODS OF FERMENTATION THEREOF | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2022-06-02 | — | — | WO | claimed |
| CN-106943441-B | Coreopsis tinctoria extract and application thereof in preparation of antidepressant drugs | 浙江大学 | 2022-05-31 | — | — | CN | claimed |
| CN-114555681-A | Multilayer dissolvable solid article comprising a coating composition and method of making the same | 宝洁公司 | 2022-05-27 | — | — | CN | claimed |
| US-20220152116-A1 | MULTI-STAGE PERSONALIZED LONGEVITY THERAPEUTICS | INSILICO MEDICINE IP LIMITED (HK) | 2022-05-19 | — | — | US | claimed |
| WO-2022101490-A1 | EUTECTIC COMPOSITIONS, METHODS AND USES THEREOF | UNIVERSIDADE DO MINHO (PT) | 2022-05-19 | — | — | WO | claimed |
| EP-3986434-A1 | A COMPOSITION FOR ENHANCEMENT OF BIOAVAILABILITY OF PHYTOCHEMICALS AND PROCESS FOR PREPARATION THEREOF | Olene Life Sciences Private Limited (IN) | 2022-04-27 | — | — | EP | claimed |
| WO-2022067405-A1 | IMMUNOMODULATORY, ANTIOXIDANT, BROAD-SPECTRUM ANTIVIRAL FOOD SUPPLEMENT BASED ON NATURAL PRODUCTS, AND USE THEREOF | GRASTI MARCELO MARTINS (BR) | 2022-04-07 | — | — | WO | claimed |
| WO-2022046668-A1 | COMPOSITIONS AND METHODS FOR REDUCING THE TRANSMISSIVITY OF ILLNESSES | MONTAGNIER LUC (US) | 2022-03-03 | — | — | WO | claimed |
| US-11260078-B2 | Method of treating senescence with multi-stage longevity therapeutics | INSILICO MEDICINE IP LIMITED (HK) | 2022-03-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260090992-A1 | COMPOSITIONS AND APPLICATIONS THEREOF | ADCYAP1R1, HNMT, HRH1 | MEN1 429/4885KMT2A 2968/4885CYP1A2 3550/4885 |
| US-20220152116-A1 | MULTI-STAGE PERSONALIZED LONGEVITY THERAPEUTICS | SENP6, SENP1, GLA | MEN1 1852/4885KMT2A 879/4885CYP1A2 1818/4885 |
| US-11260078-B2 | Method of treating senescence with multi-stage longevity therapeutics | SENP6, GLA, SENP1 | MEN1 2061/4885KMT2A 909/4885CYP1A2 1585/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | MEN1 4053/4885KMT2A 1308/4885CYP1A2 1643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.